Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
34.64
-0.07 (-0.20%)
Aug 31, 2026, 4:00 PM EDT - Market closed
Roivant Sciences Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 7.53 | 8.26 | 29.05 | 32.71 | 31.53 | 55.29 | |
Revenue Growth | -67.58% | -71.57% | -11.19% | 3.75% | -42.97% | 132.34% |
Cost of Revenue | 731.42 | 682.2 | 545.52 | 431.61 | 457.1 | 469.1 |
Gross Profit | -723.89 | -673.94 | -516.47 | -398.9 | -425.57 | -413.82 |
Selling, General & Admin | 639.59 | 605.97 | 570.21 | 380.53 | 383.45 | 425.03 |
Operating Expenses | 639.59 | 605.97 | 570.21 | 380.53 | 383.45 | 425.03 |
Operating Income | -1,363 | -1,280 | -1,087 | -779.43 | -809.01 | -838.85 |
Interest Expense | - | - | - | - | - | -7.04 |
Interest & Investment Income | 166.71 | 178.11 | 258.38 | 146.43 | 32.18 | 0.37 |
Other Non Operating Income (Expenses) | -39.89 | -43.69 | 5.04 | -60.4 | -18.87 | 73.06 |
EBT Excluding Unusual Items | -1,229 | -1,145 | -823.27 | -693.4 | -795.7 | -772.46 |
Gain (Loss) on Sale of Investments | 160.81 | 105.05 | 55.19 | -47.97 | -20.82 | 356.46 |
Gain (Loss) on Sale of Assets | 11.03 | 11.03 | 113.5 | 5,381 | 29.28 | 5.04 |
Legal Settlements | 770.63 | 770.24 | - | - | - | - |
Other Unusual Items | -3.29 | -5.4 | -27 | -45.5 | - | -372.9 |
Pretax Income | -289.88 | -264.58 | -681.59 | 4,568 | -884.99 | -923.75 |
Income Tax Expense | 124.72 | 133.33 | 48.17 | 21.5 | 4.08 | 0.37 |
Earnings From Continuing Operations | -414.6 | -397.91 | -729.76 | 4,546 | -889.07 | -924.12 |
Earnings From Discontinued Operations | - | - | 373.03 | -315.15 | -226.39 | - |
Net Income to Company | -414.6 | -397.91 | -356.73 | 4,231 | -1,115 | -924.12 |
Minority Interest in Earnings | 148.35 | 98.14 | 184.75 | 117.72 | 106.43 | 78.85 |
Net Income | -266.25 | -299.77 | -171.98 | 4,349 | -1,009 | -845.26 |
Net Income to Common | -266.25 | -299.77 | -171.98 | 4,349 | -1,009 | -845.26 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 704 | 694 | 725 | 783 | 713 | 670 |
Shares Outstanding (Diluted) | 704 | 694 | 725 | 831 | 713 | 670 |
Shares Change | -1.06% | -4.35% | -12.71% | 16.59% | 6.43% | 6.30% |
EPS (Basic) | -0.38 | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 |
EPS (Diluted) | -0.49 | -0.54 | -0.24 | 5.23 | -1.42 | -1.26 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -821.06 | -758.56 | -844.05 | -766.65 | -856.08 | -695.17 |
Free Cash Flow Per Share | -1.17 | -1.09 | -1.16 | -0.92 | -1.20 | -1.04 |
Operating Margin | -18102.46% | -15495.19% | -3740.34% | -2382.63% | -2565.86% | -1517.29% |
Profit Margin | -3534.96% | -3629.19% | -591.96% | 13294.18% | -3200.22% | -1528.89% |
Free Cash Flow Margin | -10901.00% | -9183.51% | -2905.21% | -2343.56% | -2715.14% | -1257.40% |
EBITDA | -1,361 | -1,277 | -1,073 | -757.39 | -790.16 | -832.92 |
D&A For EBITDA | 2.85 | 3.35 | 14.07 | 22.04 | 18.86 | 5.93 |
EBIT | -1,363 | -1,280 | -1,087 | -779.43 | -809.01 | -838.85 |
Effective Tax Rate | - | - | - | 0.47% | - | - |
Revenue as Reported | - | - | - | - | - | 55.29 |